Beam Therapeutics Q3 net loss widens to $134.4 million; revenue falls to $307,000
Beam Therapeutics reported third quarter 2026 results on November 3, 2026, with a net loss of $134.4 million, or $1.28 per share, up from $112.6 million, or $1.10 per share, a year earlier. License and collaboration revenue fell to $307,000 from $9.7 million, and cash, cash equivalents and marketable securities declined to $1.0 billion. The company said its cash plus an expected $200 million from its Sixth Street facility should fund operations into mid-2029, and that a U.S. BLA submission for risto-cel is expected as early as year-end 2026.
Key points
- License and collaboration revenue was $307,000 in Q3 2026 versus $9.7 million in Q3 2025.
- Net loss was $134.4 million, or $1.28 per share, versus $112.6 million, or $1.10 per share, a year earlier.
- R&D expenses were $110.1 million and G&A expenses were $31.5 million, up from $26.7 million.
- Cash position was $1.0 billion as of September 30, 2026, versus $1.2 billion at December 31, 2025; runway extends into mid-2029.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.